Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy.

Literature DB >> 17704999

Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy.

Kazuhiro Imai¹, Seizo Yamamoto, Yorito Anamizu, Toshiyuki Horiuchi.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Alendronate

Year: 2007 PMID： 17704999 DOI： 10.1007/s00774-007-0771-y

Source DB: PubMed Journal: J Bone Miner Metab ISSN： 0914-8779 Impact factor: 2.626

× No keyword cloud information.

21 in total

1. Long-term safety of bisphosphonates.

Authors: Susan M Ott
Journal: J Clin Endocrinol Metab Date: 2005-03 Impact factor: 5.958

2. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

Authors: H A Pols; D Felsenberg; D A Hanley; J Stepán; M Muñoz-Torres; T J Wilkin; G Qin-sheng; A M Galich; K Vandormael; A J Yates; B Stych
Journal: Osteoporos Int Date: 1999 Impact factor: 4.507

3. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors: T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal: J Bone Miner Res Date: 2000-04 Impact factor: 6.741

4. Changes in biochemical markers of bone in patients with insufficiency fractures.

Authors: Kenji Takahara; Mikio Kamimura; Hiroyuki Nakagawa; Shigeharu Uchiyama
Journal: J Bone Miner Metab Date: 2004 Impact factor: 2.626

5. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.

Authors: J R Tucci; R P Tonino; R D Emkey; C A Peverly; U Kher; A C Santora
Journal: Am J Med Date: 1996-11 Impact factor: 4.965

6. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors: U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal: N Engl J Med Date: 1995-11-30 Impact factor: 91.245

7. Effects of differences in mineralization on the mechanical properties of bone.

Authors: J D Currey
Journal: Philos Trans R Soc Lond B Biol Sci Date: 1984-02-13 Impact factor: 6.237

8. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Authors: J P Devogelaer; H Broll; R Correa-Rotter; D C Cumming; C N De Deuxchaisnes; P Geusens; D Hosking; P Jaeger; J M Kaufman; M Leite; J Leon; U Liberman; C J Menkes; P J Meunier; I Reid; J Rodriguez; A Romanowicz; E Seeman; A Vermeulen; L J Hirsch; A Lombardi; K Plezia; A C Santora; A J Yates; W Yuan
Journal: Bone Date: 1996-02 Impact factor: 4.398

9. Unsuspected sacral fractures: detection by radionuclide bone scanning.

Authors: R Schneider; J Yacovone; B Ghelman
Journal: AJR Am J Roentgenol Date: 1985-02 Impact factor: 3.959

Review 10. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry.

Authors: A Michael Parfitt
Journal: Curr Opin Nephrol Hypertens Date: 2003-07 Impact factor: 2.894

19 in total

1. Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Authors: Jun Iwamoto; Mitsuyoshi Uzawa
Journal: Clin Rheumatol Date: 2014-11-01 Impact factor: 2.980

Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy.

1. Long-term safety of bisphosphonates.

2. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

3. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

4. Changes in biochemical markers of bone in patients with insufficiency fractures.

5. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.

6. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

7. Effects of differences in mineralization on the mechanical properties of bone.

8. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

9. Unsuspected sacral fractures: detection by radionuclide bone scanning.

Review 10. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry.

1. Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Review 2. Review: epidemiology and pathophysiology of atypical femur fractures.

Review 3. [Osteoporotic fractures of the pelvis].

Review 4. [Pelvic ring fractures in the elderly. Underestimated osteoporotic fracture].

5. Bilateral ulna fractures associated with bisphosphonate therapy.

6. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.

Review 7. Clodronic acid formulations available in Europe and their use in osteoporosis: a review.

Review 8. Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports.

9. Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy.

10. Atypical metatarsal fracture in a patient on long term bisphosphonate therapy.